Home > Oncology > ELCC 2022 > Advanced Non-Small Cell Lung Cancer > No improved prognosis for concurrent versus sequential immune checkpoint inhibition and CRT in unresectable NSCLC

No improved prognosis for concurrent versus sequential immune checkpoint inhibition and CRT in unresectable NSCLC

Presented By
Dr Lukas Käsmann, University Hospital Munich, Germany
Presented by
Lukas Käsmann University Hospital Munich, Germany
Conference
ELCC 2022
Trial
Phase 3
Doi
https://doi.org/10.55788/3640a321
In a prospective study, concurrent immune checkpoint inhibition did not improve prognosis in patients with unresectable non-small cell lung cancer (NSCLC), neither in progression-free survival (PFS) nor overall survival (OS), compared with sequential immunotherapy. In patients with unresectable NSCLC, maintenance therapy with the immune checkpoint inhibitor durvalumab after completion of concurrent chemoradiotherapy (CRT), significantly improves PFS and 5-year OS [1,2]. In addition, results from the phase 2 NICOLAS trial (NCT02434081) suggested that concurrent administration of immune checkpoint inhibition (nivolumab) with CRT may improve the response rate over sequential therapy [3]. Dr Lukas Käsmann (University Hospital Munich, Germany) presented the results of a prospective, phase 3 study comparing the impact of concurrent versus sequential immune checkpoint in...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on